Literature DB >> 18313226

Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.

M H Baumann1, R D Clark, F H Franken, J J Rutter, R B Rothman.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) stimulates the transporter-mediated release of monoamines, including 5-HT. High-dose exposure to MDMA causes persistent 5-HT deficits (e.g. depletion of brain 5-HT) in animals, yet the functional and clinical relevance of such deficits are poorly defined. Here we examine functional consequences of MDMA-induced 5-HT depletions in rats. Male rats received binges of three i.p. injections of MDMA or saline, one injection every 2 h; MDMA was given at a threshold pharmacological dose (1.5 mg/kgx3, low dose) or at a fivefold higher amount (7.5 mg/kgx3, high dose). One week later, jugular catheters and intracerebral guide cannulae were implanted. Two weeks after binges, rats received acute i.v. challenge injections of 1 and 3 mg/kg MDMA. Neuroendocrine effects evoked by i.v. MDMA (prolactin and corticosterone secretion) were assessed via serial blood sampling, while neurochemical effects (5-HT and dopamine release) were assessed via microdialysis in brain. MDMA binges elevated core temperatures only in the high-dose group, with these same rats exhibiting approximately 50% loss of forebrain 5-HT 2 weeks later. Prior exposure to MDMA did not alter baseline plasma hormones or dialysate monoamines, and effects of i.v. MDMA were similar in saline and low-dose groups. By contrast, rats pretreated with high-dose MDMA displayed significant reductions in evoked hormone secretion and 5-HT release when challenged with i.v. MDMA. As tolerance developed only in rats exposed to high-dose binges, hyperthermia and 5-HT depletion are implicated in this phenomenon. Our results suggest that MDMA tolerance in humans may reflect 5-HT deficits which could contribute to further dose escalation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313226      PMCID: PMC2390896          DOI: 10.1016/j.neuroscience.2008.01.007

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  67 in total

1.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.

Authors:  G Battaglia; S Y Yeh; E O'Hearn; M E Molliver; M J Kuhar; E B De Souza
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

2.  Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination.

Authors:  Amy K Goodwin; Dori M Pynnonen; Lisa E Baker
Journal:  Pharmacol Biochem Behav       Date:  2003-03       Impact factor: 3.533

Review 3.  Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.

Authors:  Rafael de la Torre; Magí Farré
Journal:  Trends Pharmacol Sci       Date:  2004-10       Impact factor: 14.819

Review 4.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

5.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

Review 6.  3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.

Authors:  Michael H Baumann; Xiaoying Wang; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.530

Review 7.  Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?

Authors:  William E Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2006-03-23       Impact factor: 4.530

8.  Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan.

Authors:  X Wang; M H Baumann; C M Dersch; R B Rothman
Journal:  Neuroscience       Date:  2007-07-12       Impact factor: 3.590

9.  Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.

Authors:  D M Stone; K M Merchant; G R Hanson; J W Gibb
Journal:  Neuropharmacology       Date:  1987-12       Impact factor: 5.250

10.  Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.

Authors:  Suzanne L Verheyden; John A Henry; H Valerie Curran
Journal:  Hum Psychopharmacol       Date:  2003-10       Impact factor: 1.672

View more
  32 in total

1.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

2.  The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Authors:  Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

3.  Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Authors:  Samanta Yubero-Lahoz; Mario A Ayestas; Bruce E Blough; John S Partilla; Richard B Rothman; Rafael de la Torre; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2011-11-03       Impact factor: 4.432

4.  (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

Authors:  Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

5.  The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Authors:  K S Murnane; H L Kimmel; K C Rice; L L Howell
Journal:  Horm Behav       Date:  2011-12-14       Impact factor: 3.587

6.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

7.  Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan
Journal:  Ann Forensic Res Anal       Date:  2017-03-07

8.  (+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks.

Authors:  Matthew R Skelton; Jessica A Able; Curtis E Grace; Nicole R Herring; Tori L Schaefer; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  Neuropharmacology       Date:  2008-07-12       Impact factor: 5.250

Review 9.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

10.  Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice.

Authors:  María Juliana Orejarena; Fernando Berrendero; Rafael Maldonado; Patricia Robledo
Journal:  Psychopharmacology (Berl)       Date:  2009-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.